Merck's stock falls as the full-year revenue and profit outlooks were below expectations.
Merck recorded higher revenue in its fourth quarter, but expects earnings growth to slow as it ramps up acquisitions.
Merck & Co. reports Q4 2025 earnings on Tuesday, Feb. 3, 2026, before market open.
Merck (MRK) reached $110.42 at the closing of the latest trading day, reflecting a +1.92% change compared to its last close.
Merck heads into Q4 earnings with strong Keytruda demand and new product launches, but declining estimates and M&A costs cloud the near-term outlook.
Merck (MRK) closed at $108.34 in the latest trading session, marking a +1.35% move from the prior day.
Looking beyond Wall Street's top-and-bottom-line estimate forecasts for Merck (MRK), delve into some of its key metrics to gain a deeper insight into the company's potential performance for the quarter ended December 2025.
Merck (MRK) has been one of the stocks most watched by Zacks.com users lately. So, it is worth exploring what lies ahead for the stock.
MRK's focus shifts beyond Keytruda in Q4 as investors watch new products Capvaxive and Winrevair, as well as Animal Health business sales performance.
Merck (MRK)'s stock surged by 41% in the last six months, driven not only by a modest revenue increase but also by a significant profit jump and heightened investor confidence.
The recommendations of Wall Street analysts are often relied on by investors when deciding whether to buy, sell, or hold a stock. Media reports about these brokerage-firm-employed (or sell-side) analysts changing their ratings often affect a stock's price.
Merck (MRK) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.